Immune Regulation News

Immune Regulation News is an online resource covering research into the regulation, suppression, and modulation of the immune system.

Subscribe|Follow Us On

CAR-Mediated Release of IL-10 Increases the Function of Regulatory T Cells: Relevance for Future Clinical Application

February 6, 2026

[Molecular Therapy] Researchers used their HLA-A*02 CAR and immunosuppressive IL-10 as model components to generate human CAR-Tregs that release IL-10 upon CAR-engagement.

MSCs-Derived CRABP2 Regulates Treg/CXCL1 to Ameliorate Alcohol-Induced Liver Injury

February 5, 2026

[Cell Communication and Signaling] Researchers performed MSC infusion on an animal model of acute-on-chronic alcohol-induced liver injury. MSC therapy ameliorated liver damage, and elevated the proportion of Tregs by secreting cellular retinoic acid binding protein 2 (CRABP2).

From Pathogenesis to Therapy: The Emerging Role of Regulatory T Cells in Amyotrophic Lateral Sclerosis

February 5, 2026

[Journal of Neuroinflammation] The authors summarize recent advances in understanding Treg biology in amyotrophic lateral sclerosis, including their dynamic alterations across different disease stages and their potential immunoregulatory mechanisms

Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103

February 4, 2026

[Tr1X (Businesswire)] Tr1X announced the first clinical data from its ongoing Phase I study of TRX103 in patients with hematologic malignancies undergoing HLA-mismatched hematopoietic peripheral stem cell transplantation.

SUMOylation Is Destined for Regulatory T Cell-Related Immune Dysregulation

February 4, 2026

[Cell Death Discovery] The authors explore the multifaceted roles of SUMOylation in Treg cell biology, emphasizing its influence on differentiation, maturation, transcriptional and epigenetic regulation, and metabolic reprogramming.

Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

January 29, 2026

[Biogen, Inc. ] Biogen Inc. announced that the US FDA has granted Breakthrough Therapy Designation for litifilimab for the treatment of cutaneous lupus erythematosus (CLE). Litifilimab is a first in-class, humanized IgG1 monoclonal antibody targeting blood dendritic cell antigen 2.

Immune Checkpoint-Engineered Virus-Like Particles Induce Antigen-Specific Immune Tolerance and Protect against Food Allergy

January 29, 2026

[NPJ Vaccines] Scientist developed a novel class of tolerogenic vaccines based on recombinant virus-like particles, engineered to display the immune checkpoint molecule CTLA-4 on their surface and incorporate specific antigens.

The E3 Ligases Itch and WWP2 Regulate Autoimmune Neuroinflammation by Controlling TH2 to TH17 Cell Conversion via Interleukin-4-STAT5 Axis in Mice

January 29, 2026

[Nature Communications] The authors showed that the JAK3/STAT5 signaling pathway is critical for maintaining TH2 lineage stability by modulating Blimp1 and c-Maf thereby suppressing TH17 differentiation.

DOCK8 and STAT3 Cooperate to Restrain IgE-Inducing T Follicular Helper Cells

January 29, 2026

[Journal of Experimental Medicine] Investigators showed that DOCK8 promotes STAT3 activity, which inhibits GATA3 in T cells.

Loss of SOCS1 in Donor T Cells Exacerbates Intestinal GVHD by Driving a Chemokine-Dependent Pro-Inflammatory Immune Microenvironment

January 29, 2026

[Advanced Science] Using T cell-specific Socs1 knockout models, researchers showed that Suppressor of Cytokine Signaling 1 (SOCS1) loss intrinsically drives pro-inflammatory T cell differentiation independent of antigen stimulation, with the strongest effects observed in CD8+ T cells.

CD318 Expression Defines a Novel Subset of Human CD8 Regulatory T Cells

January 29, 2026

[Science Advances] Investigators examined the development, phenotype, and suppressive functions of CD318+ CD8 T cells. They discovered that CD8 T cells in peripheral blood mononuclear cells expresse CD318 after activation, and that the expression levels were higher than in CD4 T cells.

Selective Disruption of Lipid Peroxide Homeostasis in Intratumoral Regulatory T Cells by Targeting FSP1 Enhances Cancer Immunity

January 29, 2026

[Science Advances] Researchers showed that ferroptosis suppressor protein 1 (FSP1) is critically required for Treg resistance to ferroptosis and their immunosuppressive function within the tumor microenvironment.

For over a decade, Immune Regulation News has been keeping the scientific community up-to-date with the latest research and reviews related to immune regulation. Key research areas covered include the roles of regulatory T cells (Treg cells) in autoimmunity and self-reactivity, as well as immune response to disease, transplantation and cancer. We also provide vital updates on the latest jobs and upcoming events in the field of immunology.